| Literature DB >> 36091757 |
Congying Liu1, Shengguang Wang1, Zedong Xiang1, Tong Xu1, Mengyuan He1, Qing Xue1, Huaying Song1, Peng Gao1, Zhufeng Cong2.
Abstract
Atractylodes macrocephala Koidz (AM), traditional Chinese medicine (TCM) with many medicinal values, has a long usage history in China and other oriental countries. The phytochemical investigation revealed the presence of volatile oils, polysaccharides, lactones, flavonoids, and others. The polysaccharides from AM are important medicinal components, mainly composed of glucose (Glc), galactose (Gal), rhamnose (Rha), arabinose (Ara), mannose (Man), galacturonic acid (GalA) and xylose (Xyl). It also showed valuable bioactivities, such as immunomodulatory, antitumour, gastroprotective and intestinal health-promoting, hepatoprotective, hypoglycaemic as well as other activities. At the same time, based on its special structure and pharmacological activity, it can also be used as immune adjuvant, natural plant supplement and vaccine adjuvant. The aim of this review is to summarize and critically analyze up-to-data on the chemical compositions, biological activities and applications of polysaccharide from AM based on scientific literatures in recent years.Entities:
Keywords: Atractylodes macrocephala Koidz.; application; biological activity; chemical composition; polysaccharide
Year: 2022 PMID: 36091757 PMCID: PMC9452894 DOI: 10.3389/fphar.2022.952061
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
The chemical composition of polysaccharides from AM.
| Name | kDa | Monosaccharide composition | Structural feature | Method | Ref |
|---|---|---|---|---|---|
| RAMP-1 | 32.8 | Ara: Gal: Glc: Man = 1: 0.74: 1.88: 1.07 | →3-β-Glc | ELSD, IR, PC, GC, GC-MS, FGC/SAW |
|
| RAMP | Ara: Gal: Glc: Man = 1: 0.74: 1.88: 1.07 | GC, GC-MS, FGC/SAW, IR |
| ||
| RAMP-2 | 4.354 | Man: GalA: Glc: Gal: Ara = 1.00: 8.58: 27.28: 3.68: 4.99 | NMR, FT-IR, HPSEC-MALLS, TEM, HPLC, SEM, HPGPC | ( | |
| RAMP-3 |
| ||||
| PAMPS | ribose (Rib): Ara: Rha: Man: Glc: Gal = 1: 4.3: 0.1: 5.7: 2.8: 2.2 | 1,6-Glc | GC-MS |
| |
| PAMPS | 220, 2.15 | Glc: Man: Ara: Gal: Xyl: Rib: Rha = 10.0: 3.2: 0.85: 0.40: 0.35: 0.17: 0.10 | 1.3-→β-D-Gal | GPC, GC-MS, NMR |
|
| UAM | 2921 | Glc | 1→3-β-D, 1→3,6-β-D | HPLC, GC, NMR, IR, UV |
|
| RAMPtp | 2.325 | Glc: Man: Rha: Ara: Gal = 10.00: 2.47: 1.75: 1.46: 0.81 | 1,3-D-Gal | NMR, HPLC, GPC, SEM |
|
| PAMK | 4.1 | Ara: Glc: Gal = 1.5: 5: 1 | α-D-Gal | GC-MS, FT-IR, HPGPC, GC, NMR |
|
| PAMK | 4.7 | Ara: Glc: Gal = 1: 1.25: 6.78 | →3-β-D-Glc | GPC-RI-MALS, IC, MS |
|
| APA | 2.1 | Ara: Glc = 1: 4.57 | GC, FT-IR, HPGPC |
| |
| PAM | 28.773 | Rha: Glc: Man: Xyl: Gal = 0.3: 2.5: 1.5: 4.1: 1.5 | GC-MS, FT-IR, HPGPC, GC, NMR |
| |
| AMP | 23.91 | Man: GalA: Glc: Ara = 12.05: 6.02: 72.29: 9.64 | HPLC, GPC |
| |
| AMP | 8.374 | Glc: Gal: Rha: Man = 7.36: 1.00: 3.05: 1.52 | α-(1→4) glycoside bond, β-(1→4) glycoside bond | HPLC, GC |
|
| PRAM2 | 19.6 | Rha: Xyl: Ara: Glc: Man: Gal = 1: 1.3: 1.5: 1.8: 2.1: 3.2 | GC-MS, HPLC, HPLC, HPSEC | ( | |
| AMP-B | Glc: Gal: Man: Ara: Rha = 3.0: 2.5: 1.3: 3.5: 1.0 | GC-MS |
| ||
| YPF-P | 3.5 | Man: Glc: Gal: Ara = 1: 239: 18.6: 19.3 | HPLC-GPC, TLC |
| |
| YY13008 | 6.545 | fructose (Fru): Glc = 40: 1 | (2→1)-β-D-Fuc | HPLC, GC, NMR, GPC-MALLS |
|
| RAMPS | 109.4 | Glc: Man: Ara: Gal: Xyl: Rib: Rha = 10.00: 3.20: 0.85: 0.34: 0.35: 0.17: 0.10 | 1→6-Glc | GPC, GC-MS, NMR, FT-IR |
|
| PSAM-1 | 136 | Rha: Ara: Man: Gal = 0.68: 3.38: 1: 4.20 | α-configurations; β-configurations | HPLC-ELSD, NMR |
|
| PSAM-2 | 104 | Xyl: Ara: Gal = 9.33: 0.64: 1 | β-configurations | HPLC-ELSD, NMR |
|
| AM-1 | 31 | Man | β-configurations | IR, UV, GC |
|
| AM-2 | 11 | Fru | β-configurations | IR, UV, GC |
|
| AMAP-1 | 137.5 | GalA, Ara, Gal, Rha | 41.5% 1,4-Gal | HPGPC, HPLC-ELSD, FT-IR, GC-MS, NMR |
|
| AMAP-2 | 161.9 | GalA, Ara, Gal, Rha | 52.7% 1,4-Gal | HPGPC, HPLC-ELSD, FT-IR, GC-MS, NMR |
|
| AMAP-3 | 85.3 | GalA, Ara, Gal, Rha | 73.1% 1,4-Gal | HPGPC, HPLC-ELSD, FT-IR, GC-MS, NMR |
|
| BZJP | 5.465 | Glc: Man: Xyl = 6.8: 3.0: 1.0 | βXyl | GC-MS, NMR, IR |
|
| BZ-3–1 | 56.5 | Glc: Man: Rha: Arab:Xyl: Gal = 1.6: 0.3: 1: 2.79: 0.1:0.3 | HPGPC, GC-MS |
| |
| BZ-3–2 | 55.9 | Glc: Man: Rha: Arab: Gal = 8.24: 2.78: 0.34: 1: 0.8 | HPGPC, GC-MS |
| |
| BZ-3–3 | 55.1 | Glc: Man = 5.49: 1 | HPGPC, GC-MS |
| |
| WAM-1 | Glc: Gal = 3.01: 1 | HPLC, GC, AFM | ( | ||
| WAM | 3.263 | Glc: Gal = 3.01: 1 | β-D-1→3-D-Glc | HPLC, GC-MS, NMR, IR, AFM |
|
| Inulin-type polysaccharide of AM | 2.265 | Glc: Fru = 1:2 | α-D-Glc | ESI-MS, NMR, IR, HPLC-ELSD |
|
FIGURE 1(A) Structure of UAM (B) Structure of inulin-type polysaccharide of AM (C) Structure of WAM (Wu et al., 2011; Wang, 2012; Lin et al., 2015).
Immunomodulatory activity mechanisms of polysaccharides from AM.
| Polysaccharide | Target | Experimental model | Action or mechanism | Ref |
|---|---|---|---|---|
| PAMK | T-cells | CTX-treated female mice | The spleen index, IL-2, IL-6, TNF-α, IFN-γ, CD28+, PLCγ-1, IP3R, NFAT, AP-1 mRNA (+); CD28+/IP3R/PLC γ-1/AP-1/NFAT signal pathway |
|
| PAMK | T-cells and B-cells | CTX-treated geese | The spleen index, T cells and B cells count (+); TLR4-MyD88-NF-κB signal pathway |
|
| PAMK | T-cells | CTX-treated geese | The index of thymus and spleen, GM-CSF, IL-1β, IL-5, IL-6, IL-4 and IL-10 (+); relative mRNA expression of novel-mir2, CD25+ and CD28+(-); novel-mir2/CTLA4/CD28+/AP-1 signal pathway |
|
| PAMK-NLC | Lymphocytes | BALB/c mice | Splenic lymphocyte number, IL-1β, IL-12, TNF-α, IFN-γ, CD3+CD4+, CD3+CD8+(+) |
|
| AMP | RAW264.7 cells | NO, TNF-α, IFN-c, NF-κB (+) |
| |
| RAMP2 | Treg cells | Female C57BL/6 mice | FoxP3, IL-10 and IL-2. mRNA expression, IL-10, IL-2, STAT5 phosphorylation level (+); IL-2/STAT5 signal pathway |
|
| RAMPtp | SMLN lymphocytes/RAW264.7 cells | Oxen | PI3K-AKT, MAPKs, NO, IL-6, IL-10, IFN-α, CCL2, CCL5(+) NF-κB, Jak-STAT and calcium signalling pathways | ( |
| AMAP-1 | RAW264.7 cells | Promoting NO release |
| |
| AMAP-2 | RAW264.7 cells | Promoting NO release |
| |
| RAMPStp | Lymphocytes | T cell number, CD4+, CD8+(+) |
| |
| polysaccharide extract of AM | Adult male and female Sprague Dawley rats | The indexes of spleen and thymus (+); the expression level of Caspase-3, Smac/DIABLO and HtrA2/Omi (-) |
| |
| PAM | DC | DCs maturation, TLR4 expression, IL-12, TNF-α(+) |
|
FIGURE 2Immunomodulation activity mechanisms of polysaccharides from AM.
Antitumour activity mechanisms of polysaccharides from AM.
| Polysaccharide | Glycosidic bond | Target | Experiment | Action or mechanism | Ref |
|---|---|---|---|---|---|
| AMPs | Glioma C6 cells |
| Mitochondrial membrane potential (-); Cyt-C, Caspase-9, Caspase-3, PARP (+) |
| |
| APA | Ara: Glc = 1.00: 4.57; pyranose rings; α-type and β-type glycosidic linkages | Eca-109 cells |
| Bcl-2, mitochondrial membrane potential (-); Bax, Cyt-C, Caspase-9, Caspase-3 (+) |
|
| AMP | Gastric cancer cells SGC-7901 |
| Bax, p53 mRNA (+); Bcl-2 (-) |
| |
| PAM | Hepatocellular carcinoma cells |
| AKT/GSK-3β phosphorylation (-), β-catenin and MMP2 protein expression (-); Wnt/β-catenin signalling pathway |
| |
| PAM | Colorectal cancer cells |
| IL-6, IFN-λ, TNF-α, NO (+); MyD88/TLR4 signalling pathway |
| |
| AMP | Mouse colon cancer CT26 cells |
| TNF-α, IL-2, CD4+/CD8+ (+); MDSCs(-); TLR4 signaling pathway |
| |
| AMP | Lung cancer cells |
| IgG, IgA, IgM, CD3+, CD4+, CD4+/CD8+ (+) |
| |
| PAMK | α-D-Galp, α-D-Glc | H22 hepatocarcinoma cells |
| Arresting the H22 tumour cells at the S phase |
|
FIGURE 3A possible mechanism by polysaccharides from AM to promote apoptosis, inhibit proliferation, migration through the mitochondrial apoptotic pathway and Wnt/β-catenin signaling pathway.
Gastroprotective and intestinal health promoting mechanisms of polysaccharides from AM.
| Polysaccharide | Function | Model | Glycosidic bond | Action or mechanism | Ref |
|---|---|---|---|---|---|
| PAM | Regulating the flora of intestinal disorders | Male SD rats | xylose | Activating and accelerating the growth of the intestinal flora |
|
| PAMPS | Accelerating migration of IEC-6 cells and treating GI mucosal injury | IEC-6 cells | Rib: Ara: Rha: Man: Glc: Gal = 1.0: 4.3: 0.1: 5.7: 2.8: 2.2 | Intracellular polyamines and Kv1.1 channel expression and activity (+), [Ca2+]cyt (+) |
|
| PAMK | Repairing the damage to the gastrointestinal mucosa |
| Promoting the development of small intestinal villi, polyamine content (+); endotoxin, CRP, IL-1β, IL-6, TNF-α(-) |
| |
| AMKP | Strengthening the small intestine epithelial barrier, protecting the gastrointestinal mucosa | IEC-6 cells | The Fructose unit β (2→1) is a fructan with a terminal end connected by an α (1→2) glucoside bond | Cell Ca2+ level (+), expression of E-cadherin, α-catenin, β-catenin (+) |
|
| RAMPtp | Protecting the intestinal barrier dysfunction induced by DSS. | IPEC-J2 | Linked by 1,3-linked β-D-Gal | Phosphorylated STAT2 protein (p-STAT2) (-); the expression of TJ protein (+), the proliferation and survival of IECs (+) |
|
| AMP | Protecting intestinal mucosal barrier function | SPF-grade male C57BL/6 mice | 1,3-β-D-Galp and 1,6-β-D-Galp | TNF-α, IL-6, IL-1β mRNA expression (-), phosphorylated STAT2 protein (p-STAT2) (-); the expression of TJ protein (+) |
|
| AMP | Treating UC, ameliorating colonic injury | Forty specific-pathogen-free (SPF)-grade male C57BL/6J mice | The expression of claudin-1, occludin, ZO-1 was regulated; the expression of mucin-2 (+) |
| |
| AMP | Improving small bowel barrier function | Weanling pigs | The expression of CDKN1A gene was regulated to inhibit the proliferation of jejunal epithelial cells; the expression of ZO-1, claudin-1 and occludin mRNA (+) | ( | |
| AMP | Repairing the mucosal injury caused by | Clean ICR male mice | Regulation of gene expression of TGF-β1 and EGFR. |
| |
| AMP | Relieving spleen deficiency and improving gastrointestinal function | SPF-grade male mice | GAS, SS (+); VIP (-) |
| |
| AMP with content over 95% | Treatment of stress ulcer | Male SD rats | SOD activity (+), Bcl-2 expression (+); Bax expression (-), MDA content (-) |
| |
| YY11901 | Relieving the gastrointestinal mucosa injury | IEC-6 cells |
|
FIGURE 4The mechanism of the hepatoprotective activity of polysaccharides from AM.
FIGURE 5Hypoglycaemic mechanisms of polysaccharides from TCM.